Consensus Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Real-time Estimate Cboe BZX Other stock markets 01:13:32 2024-05-20 pm EDT			5-day change	1st Jan Change
3.115 ^USD	-8.11%		-16.04%	-45.64%

May. 09	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	MT
May. 07	Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Caribou Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

b365ad.JW9-uB977SzKofHd5wnQobF1Ylkvm2P3Qev4-jsnhJs.RyI810dJm0mt9omu0WCC1stENg57zlPCKN6eu1J31sJwOCvyZ0-LG5DXgg~f6c09e3df2203672b2505ba89392c86e

Analyst Recommendations on Caribou Biosciences, Inc.

Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	May. 09	MT
HC Wainwright Adjusts Caribou Biosciences Price Target to $24 From $23, Maintains Buy Rating	Mar. 19	MT
Cantor Fitzgerald Initiates Caribou Biosciences at Neutral Rating	Nov. 08	MT
HC Wainwright Adjusts Caribou Biosciences Price Target to $23 From $25, Maintains Buy Rating	23-07-26	MT
HC Wainwright Adjusts Price Target on Caribou Biosciences to $26 From $27, Maintains Buy Rating	23-03-14	MT
Oppenheimer Adjusts Caribou Biosciences Price Target to $32 From $36, Maintains Outperform Rating	23-03-10	MT
Citigroup Trims Price Target on Caribou Biosciences to $38 From $39, Reiterates Buy Rating	22-08-29	MT
HC Wainwright Adjusts Caribou Biosciences' Price Target to $27 from $28, Keeps Buy Rating	22-08-18	MT
RBC Cuts Price Target on Caribou Biosciences to $19 From $22, Maintains Outperform Rating, Speculative Risk Qualifier	22-08-10	MT
Citigroup Adjusts Price Target on Caribou Biosciences to Street-High $39 From $29, Reiterates Buy Rating	22-05-13	MT
SVB Securities Raises Caribou Biosciences' Price Target to $34 From $30, Maintains Outperform Rating	22-05-12	MT
SVB Securities Raises Caribou Biosciences Price Target to $30 From $29, Outperform Rating Kept	22-05-10	MT
SVB Leerink Adjusts Caribou Biosciences' Price Target to $29 from $32, Keeps Outperform Rating	22-03-22	MT
RBC Initiates Caribou Biosciences at Outperform-Speculative Risk, Sees 'Attractive Entry Point' Ahead of Clinical Data, Sets Price Target at $22	22-02-18	MT
Brookline Capital Starts Caribou Biosciences at Buy with $19 Price Target	22-02-14	MT
Oppenheimer Initiates Caribou Biosciences With Outperform Rating, $36 Price Target	21-12-01	MT
HC Wainwright Starts Caribou Biosciences at Buy With $28 Price Target	21-11-30	MT
Citigroup Upgrades Caribou Biosciences to Buy From Neutral; Price Target is $27	21-11-15	MT
CARIBOU BIOSCIENCES : SVB Leerink Initiates Coverage on Caribou Biosciences With Outperform Rating, $32 Price Target	21-08-17	MT
CARIBOU BIOSCIENCES : Citigroup Starts Caribou Biosciences at Neutral With $27 Price Target	21-08-17	MT
CARIBOU BIOSCIENCES : BofA Securities Starts Caribou Biosciences at Buy With $30 Price Target	21-08-17	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.39 USD

Average target price

19.75 USD

Spread / Average Target

+482.60%

High Price Target

30 USD

Spread / Highest target

+784.96%

Low Price Target

10 USD

Spread / Lowest Target

+194.99%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Caribou Biosciences, Inc.

Truist Securities
HC Wainwright
Cantor Fitzgerald
Oppenheimer
Citigroup
RBC Capital Markets
SVB Securities LLC
SVB Leerink
Brookline Capital Markets
BofA Securities

Ratings for Caribou Biosciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar